We consider all the information contained in this application proprietary and confidential. Please be advised that the confidentiality of all enclosed information is provided for under 18 USC, Section 1905 and/or USC, Section 331j.

Sincerely yours,
Smellance

Samuel D. Swetland

Vice President, Regulatory Affairs and Compliance

SDS/sds
DUSANDA Documents/Cover Letter-8.doc

APPEARS THIS WAY ON ORIGINAL





September 30, 1998



Olga Cintron, Project Manager
Division of Dermatologic and Dental Drug Products (HFD-540)
Center for Drug Evaluation and Research
Food and Drug Administration
2nd Floor North
9201 Corporate Boulevard
Rockville, MD 20850

REFERENCE: New Drug Application for Levulan® (aminolevulinic acid HCI)

Kerastick™ for Topical Solution, 20% - NDA No. 20-965

Dear Olga:

Attached please find copies of two correspondences submitted regarding the above application. This information was provided directly to the requesting parties as a result of a telephone correspondence. In each case, no new information has been provided that was not available in the original NDA submission. These correspondences are being provided to you for informational purposes and to maintain a record of the NDA correspondence. Please feel free to call me if you have any questions regarding either of these correspondences.

Sincerely yours,

Samuel D. Swetland

Smuel V. Swell

Vice President, Regulatory Affairs and Compliance

SDS/sds
DUSAWDA Documents/Cover Letter-6.do



DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION

PPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations, 314 & 601)

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on last page.

FOR FDA	USF
---------	-----

APPLICATION NUMBER

					HEC'D
APPLICANT INFORMATION					
NAME OF APPLICANT		DATE OF SUBI	MISSION	MEG MEG	V 000
DUSA Pharmaceuticals, Inc.		September	30, 1998	MEG.	" DOC RM
TELEPHONE NO. (Include Area Code) (914) 747-4300		FACSIMILE (FA (914) 74	30, 1998 V) Number <i>(Include</i> 7–7563	Area Code (1773)	A DOC RM
APPLICANT ADDRESS (Number, Street, City, State, Country, Zl. U.S. License number if previously issued):	P Code or Mail Code, and	AUTHORIZED U.S	i. AGENT NAME & A ne & FAX number) If	DDRESS (Number	
400 Columbus Avenue Valhalla, NY 10595		Guidelines, Inc. 10320 USA Today Way Miramar, FL 33025 (954) 433-7480 FAX: (954) 432-9015			
PRODUCT DESCRIPTION					
NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOL	OGICS LICENSE APPLIC	CATION NUMBER (f previously issued)	20-965	
ESTABLISHED NAME (e.g., Proper name, USP/USAN name) PROPRIETARY, Aminolevulinic Acid HCl Levulan		PRIETARY NAME (1 evulan Keras	<i>trade name)</i> IF ANY stick ^[M]		
CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (If any) 5-amino-4-oxopentanoic acid			CODE NAME	E (11 any) HC] . 5-ALA . I	NA.
DOSAGE FORM: STRENGTHS Solution	20%	R	oute of administ Topical	TRATION:	
(PROPOSED) NOICATION(S) FOR USE: Treatment of actinic keratoses of the face and scalp LICATION INFORMATION					
APPLICATION TYPE (check one) DE NEW DRUG APPLICATION (21 CFR 314.50) ABBREVIATED APPLICATION (ANDA, AADA, 21 CFR 314.94) BIOLOGICS LICENSE APPLICATION (21 CFR part 601)					
IF AN NDA, IDENTIFY THE APPROPRIATE TYPE (\$\frac{1}{2}\) 505 (b) (1)					
IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION Name of Drug Holder of Approved Application					
TYPE OF SUBMISSION (check one)	AMENDMENT TO A PEND	NG APPLICATION	☐ RE	SUBMISSION	
PRESUBMISSION ANNUAL REPORT	☐ ESTABLISHM	ENT DESCRIPTION &	JPPLEMENT	SUPAC SUPPLE	MENT
☐ EFFICACY SUPPLEMENT ☐ LABELING SUPPLE	EMENT CHE	IISTRY MANUFACTUR	RING AND CONTROLS	SUPPLEMENT	(C) OTHER
REASON FOR SUBMISSION General Correspondence	æ				
PROPOSED MARKETING STATUS (check one) PRESCRIPTION PRODUCT (Rb) OVER THE COUNTER PRODUCT (OTC)					
NUMBER OF VOLUMES SUBMITTED 1	THIS APPLICATION I	S 🖾 PAPER	PAPER AN	D ELECTRONIC	ELECTRONIC
ESTABLISHMENT INFORMATION					
Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessar y). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.					
See Attachment to Form FDA 356h					
Communications (list related License Applications, I loation)	NDs, NDAs, PMAs, 51	0(k)s, IDEs, BMF	Fs, and DMFs ref	erenced in the c	urrent





September 30, 1998

Richard Felten, PhD
Division of General and Restorative Devices
Office of Device Evaluation
Center for Device and Radiological Health
Food and Drug Administration
HFZ-410, Room 310K
9200 Corporate Boulevard
Rockville, MD 20850

REFERENCE: DESK COPY -

New Drug Application for Levulan® (aminolevulinic acid HCI)

Kerastick™ for Topical Solution, 20% - NDA No. 20-965

Dear Dr. Felten:

On behalf of our client, DUSA Pharmaceuticals, Inc., and pursuant to our phone conversation yesterday regarding the above referenced NDA, attached please find additional copies of the following NDA volumes:

1. Volume 1.1.1

2. Volume 1.10.1

3. Volume 1.10.2

If you require any further information please feel free to call me.

Sincerely yours,

Samuel D. Swetland

Vice President, Regulatory Affairs and Compliance

CC: NDA 20-965

SDS/sds

DUSAWDA Documents/Cover Letter-7.doc







September 18, 1998

Jose Carreras, MD
Division of Scientific Investigations (HFD-344)
Center for Drug Evaluation and Research
Food and Drug Administration
Metro Park North 1, Room 125
7520 Standish Place
Rockville, MD 20855

REFERENCE: New Drug Application for Levulan® (aminolevulinic acid HCI)

Kerastick™ for Topical Solution, 20% - NDA No. 20-965

Dear Dr. Carreras:

On behalf of our client, DUSA Pharmaceuticals, Inc., and pursuant to our phone conversation yesterday regarding the above referenced NDA, attached please find the requested information as outlined below.

- 1. A list of the names and addresses of the clinical investigators who participated in the Phase III clinical trials (Protocols ALA-018 and ALA-019).
- 2. The number of patients enrolled in each center (Protocols ALA-018 and ALA-019) by treatment arm.
- 3. A list of all serious adverse reactions for Protocols ALA-018 and ALA-019.

Please note that the page numbers on the bottom right corner of each page reference the location of this data in the original NDA submission. If you require any further information please feel free to call me.

Sincerely yours, ...

Samuel D. Swetland

Somuel D. Swellan

Vice President, Regulatory Affairs and Compliance

SDS/sds
DUSAWDA Documental/Cover Letter-5.doc



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

